NCT02454088已完成不适用
A Single-Center Investigator-Initiated Evaluator-Bilateral-Comparison Pilot Study of Injectable Calcium Hydroxylapatite With and Without Triamcinolone Acetate for the Treatment of Volume Loss to Dorsum Areas of the Hands
Goldman, Butterwick, Fitzpatrick and Groff2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2015年5月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Efficacy Analysis (Merz Validated Hand Grading Score)
研究概览
简要总结
This will be a single-center, investigator-initiated, double-blinded, randomized, bilateral-comparison pilot study of injectable Calcium hydroxylapatite with and without Triamcinolone acetate for the treatment of volume loss to the dorsum areas of the hands.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Cutaneous and soft tissue atrophy in the dorsum of both hands, as indicated by the Merz Validated Hand Grading Scale score of 2, 3 or
- •Males or females in good general health who are 22 years of age or older.
- •Must be willing to give and sign an informed consent form and photographic release form.
- •Subject is planning re-volumizing rejuvenation treatment to the dorsum area of both hands.
- •For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment participation.
- •A female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation.
- •Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g. condoms and spermicide), abstinence and/or vasectomies of partner with a documented second acceptable method of birth control, should the subject become sexually active.
- •Negative urine pregnancy test results at the time of study entry (if applicable).
- •Must be willing to comply with study dosing and complete the entire course of the study.
排除标准
- •A subject with any uncontrolled systemic disease. A potential subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study.
- •A Subject that is currently using systemic steroids.
- •A subject with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
- •A subject with history of or the presence of any skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis).
- •A subject with an active bacterial, fungal, or viral infection in the treatment area.
- •A subject with an active systemic fungal infection.
- •A subject with a prior history of an allergy to any of the products or medications being used in the study.
- •A subject planning any other cosmetic procedure to the study area during the study period, other than the treatments that will be performed by the investigator.
- •A subject with a history of previous fat transfer or injectable poly-l-lactic acid to the study area within the past five years.
- •A subject with a previous history of calcium hydroxylapatite to the treatment area within the past year.
- •A subject with a previous history of ablative laser surgery to the treatment area within the past year.
- •A female subject who is pregnant, nursing an infant or planning a pregnancy during the study.
- •Subjects with known autoimmune disease or compromised immune systems i.e. HIV, AIDS or current chemotherapy.
- •Subjects with known bleeding disorder or is receiving medication that will likely increase the risk of bleeding as the result of injection per investigator discretion.
- •Subjects with a history hypertrophic scarring.
- •Subjects with a cancerous or precancerous lesion, or unhealed wound in the treatment area.
- •Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.
结局指标
主要结局
Efficacy Analysis (Merz Validated Hand Grading Score)
时间窗: Through day 360
The primary analyses of efficacy will be based on the change from Baseline through Day 360 for assessment (based on the Merz Validated Hand Grading Score).
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular EczemaNummular EczemaEczemaDermatitis EczemaNummular DermatitisNCT03160248Technical University of Munich31
终止
不适用
A Randomized Clinical Study Comparing Two Closure Techniques of Excised KeloidsKeloidNCT00519493University of Miami3
已完成
4 期
Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation TimesActinic KeratosesNCT02622594Dermatology, Laser & Vein Specialists of the Carolinas10
已完成
1 期
A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and MoxifloxacinAcute Coronary SyndromeNCT01756495GlaxoSmithKline56
招募中
1 期
First-in-Human Study of VB0004 in Healthy Subjects and to Patients With Mild to Moderate Hypertension With Low Cardiovascular RiskHypertensionNCT04925050Syneos Health88